GeneTex
United States (US)

BACE2 peptide

Cat No. GTX28391

Application Blocking
Species Human
APPLICATION

Application Note

The peptide is used for blocking the antibody activity of GTX28024. Itusually blocks the antibody activity completely in Western blot by incubating the peptide withequal volume of antibody for 30 min at 37ºC
PROPERTIES

Form

Liquid

Buffer

PBS pH7.2 with 10 mM NaH2PO4, 10 mM Na2HPO4, 130 mM NaCl, 0.1% bovine serum albumin, and 0.02% sodium azide

Storage

Store the peptide at -20˚C, stable for one year.

Concentration

0.20 mg/ml (Please refer to the vial label for the specific concentration.)

Conjugation

Unconjugated

Note

For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
TARGET

Synonyms

Beta-Secretase 2,Aeplc,Alp56,Asp1,Asp21,Bae2,Cda13,Ceap1,Drap,Bace2

Background

Accumulation of the abeta in plaques in the cerebral cortex is a critical event in the pathogenesis of Alzheimers disease. Abeta peptide is generated by proteolytic cleavage of the b-amyloid protein precursor(APP) at by secretases. BACE/Asp2 is a novel transmembrane aspartic protease and co-localizes with APP. A BACE homolog was cloned and designated BACE2, Asp1, DRAP (for Down region aspartic protease), and memapsin 1. BACE2 also cleaves APP at b-site and at a different site within Ab. BACE2 locates on chromosome 21q22.3, the so-called Down critical region, suggesting that BACE2 and Ab may also contribute to the pathogenesis of Down syndrome.

Research Area

Package List Price ($)
$ 179